Novartis gets USFDA warning letter for two plants in India
Sandoz, the generic drug arm of Swiss drug major Novartis, has received a warning letter from the US health regulator for violations of current good manufacturing practice (cGMP) norms at its two plants in Western India.
Oct 28, 2015, 21:05 PM IST